First in vitro and in vivo experiments with ultra high-dose rate oxygen ion radiotherapy
Within this study, we demonstrated the feasibility of ultra-high dose rate (UHDR) oxygen ion irradiation at three different levels of biological complexity. The difference in oxygen consumption between UHDR and standard dose rates (SDR) was negligible in a protein-enriched saline solution. For the studied conditions of dose, dose rate and linear energy transfer (LET), UHDR irradiation showed comparable efficacy to SDR in pancreatic cancer cell killing in vitro, along with inducing a similar tumor growth delay in vivo. These findings emphasize the potential of high-LET UHDR irradiation and support further investigation of oxygen ions at UHDR.
Authors
- Stephan Brons (ORCID: https://orcid.org/0000-0002-4695-0816)
- Nora Schuhmacher
- R. Cee
- Thomas Tessonnier (ORCID: https://orcid.org/0000-0002-8919-4299)
- Ivana Đokić
- Mahdi Akbarpour
- Amir Abdollahi (ORCID: https://orcid.org/0000-0002-8016-5897)
- Jürgen Debus (ORCID: https://orcid.org/0000-0002-6411-4811)
- Christian Schömers (ORCID: https://orcid.org/0000-0001-5605-0953)
- Thomas Haberer
- Mahmoud Moustafa (ORCID: https://orcid.org/0000-0002-9146-0808)
- Kristoffer Petersson (ORCID: https://orcid.org/0000-0003-0300-5790)
- Stefan Scheloske
- Andrea Mairani (ORCID: https://orcid.org/0000-0001-6669-7064)
- Domenico Ivan Filosa
- Celine Karle
Institutions
- Suez Canal University (EG)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University of Oxford (GB)
- Heidelberger Institut für Radioonkologie (DE)
- National Center for Oncological Hadrontherapy (IT)
- CRUK/MRC Oxford Institute for Radiation Oncology (GB)
- National Center for Tumor Diseases (DE)
Publication Details
- Journal
- Physics and Imaging in Radiation Oncology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1016/j.phro.2025.100803
- Citations
- 1
- Primary Topic
- Radiation Therapy and Dosimetry
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Nationales Centrum für Tumorerkrankungen Heidelberg
- National Institutes of Health